Inhibition of caspase-1 ameliorates tauopathy and rescues cognitive impairment in SAMP8 mice

Metab Brain Dis. 2022 Apr;37(4):1197-1205. doi: 10.1007/s11011-022-00914-9. Epub 2022 Feb 10.

Abstract

The inflammasome assembles leading to increased cleavage and activity of caspase-1 and downstream IL-1β release, which plays a significant role in the pathogenesis of Alzheimer's disease (AD). Previous studies have shown that caspase-1-mediated neuroinflammation occurs early in AD process. However, the detailed role of caspase-1 in aging-related AD-like neuropathology is still unclear so far. In this study, by using SAMP8 mice, an animal model of accelerated aging, we detected the levels of caspase-1 in brains of 3-, 7-, and 11-month-old mice and observed that caspase-1 was activated during aging process. More importantly, we provided the evidence that VX-765, a selective inhibitor of caspase-1, significantly rescued spatial learning and memory impairments and reduced tau hyperphosphorylation in brains of SAMP8 mice at early stages of the disease. This amelioration might be attributed to IL-1β-induced hypoactivation of tau kinases. Our results imply that caspase-1 may represent as a potential therapeutic target for neurodegenerative tauopathies.

Keywords: Caspase-1; SAMP8; Spatial cognitive deficits; Tau hyperphosphorylation; VX-765.

MeSH terms

  • Alzheimer Disease*
  • Animals
  • Caspase 1 / metabolism*
  • Cognitive Dysfunction* / drug therapy
  • Memory Disorders
  • Mice
  • Tauopathies* / drug therapy

Substances

  • Casp1 protein, mouse
  • Caspase 1